Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
Public ClinicalTrials.gov record NCT00085644. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
Study identification
- NCT ID
- NCT00085644
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Abbott
- Industry
- Enrollment
- 315 participants
Conditions and interventions
Conditions
Interventions
- adalimumab (D2E7) Biological
- placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2003
- Primary completion
- Nov 30, 2004
- Completion
- Jun 30, 2009
- Last update posted
- Apr 20, 2011
2004 – 2009
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35924 | — |
| Not listed | Mobile | Alabama | 36608 | — |
| Not listed | San Francisco | California | 94143 | — |
| Not listed | Colorado Springs | Colorado | 80910 | — |
| Not listed | Denver | Colorado | 80230 | — |
| Not listed | Boise | Idaho | 83706 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Indianapolis | Indiana | 46260 | — |
| Not listed | Portland | Maine | 04102 | — |
| Not listed | Baltimore | Maryland | 21224 | — |
| Not listed | Wheaton | Maryland | 20902 | — |
| Not listed | Omaha | Nebraska | 68114 | — |
| Not listed | Lebanon | New Hampshire | 03756 | — |
| Not listed | Albany | New York | 12206 | — |
| Not listed | Oklahoma City | Oklahoma | 73112 | — |
| Not listed | Duncansville | Pennsylvania | 16635 | — |
| Not listed | West Reading | Pennsylvania | 19611 | — |
| Not listed | Dallas | Texas | 75231 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Houston | Texas | 77074 | — |
| Not listed | Salt Lake City | Utah | 84132 | — |
| Not listed | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00085644, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2011 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00085644 live on ClinicalTrials.gov.